CAR T-therapy is a promising treatment for advanced blood cancer, but the logistics of manufacturing and transporting the therapy to patients can be challenging. Galapagos aims to address this issue by developing a technology that allows for manufacturing of the therapy at the hospital where the patient is receiving care, significantly shortening the treatment timeline. Early-stage clinical data presented by Galapagos at the annual meeting of the American Society of Hematology showed promising results, with the potential to produce CAR T-therapies in as little as seven days. The company’s technology, called Cocoon, enables the manufacturing of personalized cell therapy, with preliminary results showing positive treatment responses. The technology has the potential to revolutionize the field of cancer treatment and improve patient access to life-saving therapies.
Source link
Galapagos Counts On Cocoon to Help It Catch Up in Cancer Cell Therapy
